Amrize (NYSE:AMRZ - Get Free Report) had its target price decreased by research analysts at Wells Fargo & Company from $40.00 to $39.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has an "equal weight" rating on the stock. Wells Fargo & Company's price target would suggest a potential downside of 4.92% from the company's current price.
A number of other equities research analysts have also recently issued reports on AMRZ. Stephens cut their price objective on shares of Amrize from $65.00 to $54.00 and set an "overweight" rating for the company in a research note on Wednesday, August 12th. Citigroup cut their price objective on Amrize from $58.00 to $50.00 and set a "buy" rating on the stock in a research report on Friday, October 2nd. William Blair set a $40.00 target price on Amrize in a report on Wednesday, September 2nd. Longbow Research began coverage on Amrize in a research note on Monday, October 12th. They issued a "buy" rating for the company. Finally, Zacks Research cut shares of Amrize from a "hold" rating to a "strong sell" rating in a report on Wednesday, August 19th. Eight research analysts have rated the stock with a Buy rating, seven have given a Hold rating and four have given a Sell rating to the company's stock. According to MarketBeat, Amrize currently has an average rating of "Hold" and an average target price of $49.24.
Read Our Latest Research Report on AMRZ
Amrize Trading Down 1.4%
Shares of Amrize stock traded down $0.59 during midday trading on Friday, reaching $41.02. The company had a trading volume of 2,579,680 shares, compared to its average volume of 3,436,898. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.10 and a quick ratio of 0.73. Amrize has a fifty-two week low of $35.78 and a fifty-two week high of $65.94. The stock has a fifty day moving average price of $39.79 and a 200 day moving average price of $50.68. The firm has a market cap of $22.69 billion, a PE ratio of 18.57, a P/E/G ratio of 1.42 and a beta of 0.20.
Amrize (NYSE:AMRZ - Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The company reported $1.05 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.05. The firm had revenue of $3.77 billion for the quarter. Amrize had a return on equity of 9.96% and a net margin of 9.93%. Amrize's quarterly revenue was up 2.6% compared to the same quarter last year. During the same period last year, the firm posted $0.98 earnings per share. On average, equities analysts anticipate that Amrize will post 2.44 earnings per share for the current year.
Insider Transactions at Amrize
In other news, CFO Baris Oran purchased 3,000 shares of the stock in a transaction dated Tuesday, August 11th. The shares were purchased at an average cost of $47.38 per share, with a total value of $142,140.00. Following the acquisition, the chief financial officer directly owned 3,000 shares of the company's stock, valued at $142,140. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jacques Sanche bought 4,150 shares of the stock in a transaction on Wednesday, August 26th. The stock was purchased at an average cost of $45.02 per share, for a total transaction of $186,833.00. Following the acquisition, the director owned 9,766 shares of the company's stock, valued at $439,665.32. This trade represents a 73.90% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought 48,983 shares of company stock worth $2,158,755 over the last quarter. Corporate insiders own 0.54% of the company's stock.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the stock. National Pension Service grew its holdings in shares of Amrize by 7.5% in the second quarter. National Pension Service now owns 1,493,022 shares of the company's stock valued at $79,578,000 after purchasing an additional 103,962 shares in the last quarter. Ancora Advisors LLC lifted its position in Amrize by 22.9% during the second quarter. Ancora Advisors LLC now owns 283,522 shares of the company's stock valued at $15,112,000 after purchasing an additional 52,759 shares during the last quarter. Engle Capital Management L.P. purchased a new position in shares of Amrize in the 1st quarter worth $3,742,000. Renaissance Technologies LLC increased its holdings in shares of Amrize by 10.4% in the 1st quarter. Renaissance Technologies LLC now owns 1,956,600 shares of the company's stock worth $109,609,000 after buying an additional 183,900 shares during the last quarter. Finally, Punch & Associates Investment Management Inc. purchased a new stake in shares of Amrize during the 1st quarter valued at about $8,864,000.
Amrize Company Profile
(
Get Free Report)
Amrize is a North American building-solutions company that supplies materials and products used in residential, commercial and infrastructure construction. Its portfolio includes cement, aggregates, ready-mix concrete, asphalt, roofing systems and other building products.
The company serves customers across the United States and Canada through a network of production facilities, distribution locations and related operations. Its products support applications ranging from roads, bridges and other public infrastructure to commercial buildings and residential construction.
Amrize was formed through the separation of Holcim's North American business and began trading independently on the New York Stock Exchange under the symbol AMRZ in 2025.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amrize, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amrize wasn't on the list.
While Amrize currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.